About OverT Bio
OverT Bio is a company based in New York (United States) founded in 2022 by Neville Sanjana and Mat Legut.. OverT Bio has raised $16 million across 2 funding rounds from investors including ARE, Cancer Research Institute and ScaleReady. OverT Bio offers products and services including Cell Therapy Solutions. OverT Bio operates in a competitive market with competitors including Senti Biosciences, Caribou Biosciences, Immunocore, Autolus and Cargo Therapeutics, among others.
- Headquarter New York, United States
- Founders Neville Sanjana, Mat Legut
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Overt Bio, Inc.
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$16 M (USD)
in 2 rounds
-
Latest Funding Round
$120 K (USD), Grant
Nov 22, 2024
-
Investors
ARE
& 9 more
-
Employee Count
Employee Count
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of OverT Bio
OverT Bio offers a comprehensive portfolio of products and services, including Cell Therapy Solutions. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Innovative treatments for medical research and applications
Funding Insights of OverT Bio
OverT Bio has successfully raised a total of $16M across 2 strategic funding rounds. The most recent funding activity was a Grant round of $120 thousand completed in November 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 2
- Last Round Grant — $120,000
-
First Round
First Round
(06 May 2024)
- Investors Count 10
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Nov, 2024 | Amount | Grant - OverT Bio | Valuation |
investors |
|
| May, 2024 | Amount | Seed - OverT Bio | Valuation | Artis Ventures , Wing Venture Capital |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in OverT Bio
OverT Bio has secured backing from 10 investors, including venture fund and institutional investors. Prominent investors backing the company include ARE, Cancer Research Institute and ScaleReady. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Early-stage startups are invested in by Artis Ventures.
|
Founded Year | Domain | Location | |
|
Venture capital fund and fund of funds focused on early-stage startups
|
Founded Year | Domain | Location | |
|
Investment in early-stage startups focusing on healthcare, AI, and industrial technology.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by OverT Bio
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - OverT Bio
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Overt Bio Comparisons
Competitors of OverT Bio
OverT Bio operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Senti Biosciences, Caribou Biosciences, Immunocore, Autolus and Cargo Therapeutics, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Cell-based therapies for cancer treatment are developed.
|
|
| domain | founded_year | HQ Location |
Provider of cell therapies to treat cancer and hematologic conditions
|
|
| domain | founded_year | HQ Location |
Developer of drugs based on T-Cell receptor technology for the treatment of cancer
|
|
| domain | founded_year | HQ Location |
Engineered T-cell immunotherapies are developed for cancer and auto-immune diseases.
|
|
| domain | founded_year | HQ Location |
Cell-based therapeutics for cancer treatment are developed.
|
|
| domain | founded_year | HQ Location |
T-cell therapies targeting tumor neo-antigens for cancer are developed.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Frequently Asked Questions about OverT Bio
When was OverT Bio founded?
OverT Bio was founded in 2022 and raised its 1st funding round 2 years after it was founded.
Where is OverT Bio located?
OverT Bio is headquartered in New York, United States. It is registered at New York, New York, United States.
Who is the current CEO of OverT Bio?
Mat Legut is the current CEO of OverT Bio. They have also founded this company.
Is OverT Bio a funded company?
OverT Bio is a funded company, having raised a total of $16M across 2 funding rounds to date. The company's 1st funding round was a Seed of $16M, raised on May 06, 2024.
What does OverT Bio do?
OverT Bio was founded in 2022 in New York, United States, within the biotechnology sector focused on oncology. Cell therapies targeting solid tumors are developed through pooled functional screening and synthetic genomics platforms known as Over Target and OverTune. Next-generation engineered immune cells are created to address cancer cells, with operations centered on innovative screening methods for therapeutic advancement.
Who are the top competitors of OverT Bio?
OverT Bio's top competitors include Immunocore, Achilles Therapeutics and Autolus.
What products or services does OverT Bio offer?
OverT Bio offers Cell Therapy Solutions.
Who are OverT Bio's investors?
OverT Bio has 10 investors. Key investors include ARE, Cancer Research Institute, ScaleReady, Artis Ventures, and Wing Venture Capital.